GSK 3390107A

Drug Profile

GSK 3390107A

Alternative Names: cAd3 EBO Z; ChAd3 Ebola candidate vaccine - GSK; ChAd3-EBO-Z; Chimp Adenovirus type 3 Ebola vaccine - GSK; GSK 3390107 A; Monovalent Ebola vaccine - NIAID/Okairos; Monovalent Ebola vaccine - Okairos/NIAID; Monovalent Ebola virus vaccine - NIAID/Okairos; Monovalent Ebola virus vaccine - Okairos/NIAID; Monovalent Zaire Ebola Chimpanzee Adenovirus vector vaccine; VRC-EBOADC076-00-VP

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Okairos
  • Developer National Institute of Allergy and Infectious Diseases; ReiThera; The Jenner Institute; University Hospital of Lausanne; University of Oxford
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 01 Dec 2016 GlaxoSmithKline completes a phase-II trial in Ebola virus infections (Prevention, In volunteers) in Cameroon, Mali, Nigeria, Senegal (NCT02485301)
  • 01 Nov 2015 Phase-II clinical trials in Ebola virus infections (Prevention, In infants, In children, In adolescents) in Mali (IM)
  • 21 Sep 2015 GlaxoSmithKline plans a phase II trial for Ebola virus infections (In volunteers, In infants, In children, In adolescents) in USA, Ghana, Mali, Senegal and Nigeria (NCT02548078)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top